Skip to main content

Table 2 DEX-induced resistance in fresh patient-derived pancreatic tissue.

From: Corticosteroid co-treatment induces resistance to chemotherapy in surgical resections, xenografts and established cell lines of pancreatic cancer

Time No. of patients Drugs DEX1 DEX2 DEX3 Sum
24 h 18 0 11% 22% 11% 15%
   1 44% 78% 83% 69%
   2 44% 67% 56% 56%
   3 56% 72% 90% 72%
48 h 20 0 10% 15% 15% 13%
   1 60% 70% 90% 73%
   2 50% 75% 65% 63%
   3 60% 75% 70% 68%
72 h 18 0 56% 28% 17% 17%
   1 44% 72% 67% 61%
   2 39% 67% 67% 57v
   3 56% 67% 78% 67%
Sum of drug-treated cells 1-3    50% 71% 74%  
Sum of control cells 0    9% 22% 14%  
  1. The percentage of cells derived from 20 patients which show statistically significant chemotherapy resistance/enhanced viability in response to treatment with dexamethasone is given. For definition of resistance, please see the Material and Methods section. Time: time point after incubation with drugs; No. of patients: indicates the number of patients whose cells were freshly isolated from resected pancreatic tissue (compare Table 2); 0: without drugs, 1: low drug concentration, 2: medium drug concentration, 3: high drug concentration of gemcitabine (25, 50 200 nM) or cisplatin (7,17,34 μM). DEX1: 0.1 μM, DEX2: 1 μM, DEX3: 10 μM.